In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has given the green light to Traumagel, a game-changing device that can stop bleeding from gunshot wounds in mere seconds, as reported by Fast Company. This innovative gel-based treatment, developed by Cresilon, has the potential to save countless lives by preventing deaths from blood loss due to traumatic injuries.
Traumagel is a plant-based gel that can be easily applied to severe wounds, quickly forming a clot and stopping bleeding without the need for manual pressure. This sets it apart from traditional methods like gauze bandages, which require time-consuming preparation and application, often proving ineffective in critical situations.
The approval of Traumagel comes at a crucial time, as approximately 40% of trauma-related deaths worldwide are attributed to bleeding. By providing a rapid and efficient solution, Traumagel can significantly reduce this staggering statistic, offering hope to those in dire need of life-saving interventions.
Cresilon, the visionary company behind Traumagel, operates a state-of-the-art biomanufacturing facility in Brooklyn, ensuring a reliable supply of the device to meet the growing demand. Qz reports that the company plans to launch Traumagel in late 2024, with the product available in user-friendly, 30-ml pre-filled syringes for easy application in emergency situations.
The implications of Traumagel’s approval are far-reaching, with the potential to revolutionize emergency medicine across various sectors. From military combat situations to civilian emergency response teams, this device can make a significant difference in preventing unnecessary loss of life due to traumatic injuries.
As Cresilon continues to work closely with the Department of Defense and the Walter Reed Army Institute of Research, the future of Traumagel looks promising. With ongoing research and development, this life-saving device is poised to become a staple in emergency medical kits worldwide, offering hope and a fighting chance to those facing life-threatening bleeding.
Launch and Availability
Traumagel is set to launch in late 2024. Cresilon, the company behind Traumagel, is well-prepared to meet the anticipated demand. They operate a 33,000-square-foot biomanufacturing facility in Brooklyn, ensuring a steady supply of the device.
With its upcoming launch, Traumagel is poised to become a game-changer in emergency medicine. Its availability will provide medical professionals with a powerful tool to prevent deaths from blood loss due to traumatic injuries.
Image credit: Wikimedia
